Efficacy and Safety of Prophylactic-Dose Anticoagulation Therapy with Intermediate-Therapeutic Doses in Covid-19 Patients

Authors

  • Diva Rachma Kurniawati
  • Agus Subagjo
  • Lilik Djuari

DOI:

https://doi.org/10.37506/ijfmt.v17i1.18902

Keywords:

: COVID-19, thromboprophylaxis, anticoagulants, thrombosis, bleeding

Abstract

Introduction: Coronavirus Disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2
(SARSCoV-2) was declared a worldwide pandemic on March 11, 2020 and globally, on April 29, 2022, there were
510,270,667 confirmed COVID-19 cases, including 6,233,526 deaths, reported to WHO. As of April 2022, the
Government of the Republic of Indonesia has reported 4,249,323 confirmed cases of COVID-19. There have been
143,592 COVID-19-related deaths reported and 4,096,194 patients have recovered from the disease. COVID-19
is associated with a high risk of venous thromboembolism (VTE), however, to date, optimal prophylactic
anticoagulant therapy remains uncertain and may depend on the severity of COVID-19.
Objective: The aim of this study was to determine the difference in efficacy and safety in administering prophylactic
doses with intermediate/therapeutic doses in confirmed COVID-19 patients.
Results: This study used 6 studies that met the inclusion of differences in efficacy and safety in administering
prophylactic doses with intermediate/therapeutic doses in confirmed COVID-19 patients.
Conclusion: From 6 studies, there were 2 studies comparing anticoagulant prophylactic doses with intermediate
doses and 4 studies comparing anticoagualnt prophylactic doses with therapeutic doses. In all studies, there were
no significant differences in thromboembolic events or all-cause mortality in COVID-19 patients. The incidence of
bleeding at the intermediate and therapeutic doses increased compared to the prophylactic dose, but the difference
was not significant.

Author Biographies

  • Diva Rachma Kurniawati

    Student, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia,

  • Agus Subagjo

    Consultant, Department of Cardiology dan Vascular Medicine, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital Surabaya, Indonesia.

  • Lilik Djuari

    Consultant, Department of Public Head Science, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital Surabaya, Indonesia

Downloads

Published

2022-12-21

How to Cite

Efficacy and Safety of Prophylactic-Dose Anticoagulation Therapy with Intermediate-Therapeutic Doses in Covid-19 Patients. (2022). Indian Journal of Forensic Medicine & Toxicology, 17(1), 97-101. https://doi.org/10.37506/ijfmt.v17i1.18902